Moderna COVID-19 Vaccine

BIOLOGICAL6 trials

Conditions

Allergic ReactionCOVID-19COVID-19, Long HaulCovid19Mast Cell DisorderRheumatic DiseasesRheumatoid ArthritisSARS-CoV Infection

Phase 2

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

CompletedNCT04761822

National Institute of Allergy and Infectious Diseases (NIAID)Allergic Reaction, COVID-19, Mast Cell Disorder +1

Start: 2021-04-07End: 2022-04-27Updated: 2025-08-12

Phase 3

COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

CompletedNCT04806113

McGill University Health Centre/Research Institute of the McGill University Health CentreCovid19, Rheumatic Diseases, Rheumatoid Arthritis +1

Start: 2021-03-11End: 2022-06-15Updated: 2023-03-20

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

CompletedNCT04811664

National Institute of Allergy and Infectious Diseases (NIAID)SARS-CoV-2 Infection

Start: 2021-03-24End: 2021-12-30Updated: 2023-08-02

Phase 4

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

RecruitingNCT06441955

Well- Konnect Healthcare Services and Research FirmCOVID-19, Long Haul

Start: 2024-03-01End: 2030-09-30Target: 100Updated: 2024-11-27

Unknown Phase

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

CompletedNCT05765578

ModernaTX, Inc.COVID-19

Start: 2023-03-08End: 2024-06-17Updated: 2024-07-31

Post Authorization Safety Study Moderna COVID-19 Primary Vaccine

CompletedNCT06006858

PT Bio FarmaCOVID-19

Start: 2022-11-03End: 2023-03-31Updated: 2023-11-18

Related Papers

Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March – December 2021

UNC Libraries2025-08-25

Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.

2024-08-24

Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021

UNC Libraries2023-12-06

Efficacy of Messenger RNA–1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021

Open Forum Infectious Diseases2023-11-012 citations

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

Blood Advances2022-01-2421 citations